Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas.
Latest Information Update: 20 Mar 2025
At a glance
- Drugs Temozolomide (Primary)
- Indications Astrocytoma; Glioma; Oligodendroglioma
- Focus Pharmacogenomic; Therapeutic Use
Most Recent Events
- 17 Mar 2025 Planned End Date changed from 31 Dec 2026 to 31 Dec 2025.
- 24 Jan 2025 Planned primary completion date changed from 31 Dec 2024 to 30 Apr 2025.
- 20 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.